Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accumulated Expenses (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Accumulated Expenses readings, the most recent being $7.6 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 28.37% to $7.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.6 million, a 28.37% decrease, with the full-year FY2025 number at $6.5 million, down 81.23% from a year prior.
  • Accumulated Expenses hit $7.6 million in Q4 2025 for Enanta Pharmaceuticals, up from $6.5 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $36.7 million in Q2 2023 to a low of $2.4 million in Q4 2021.
  • Median Accumulated Expenses over the past 5 years was $10.6 million (2024), compared with a mean of $15.8 million.
  • Biggest five-year swings in Accumulated Expenses: surged 1308.1% in 2023 and later crashed 86.94% in 2024.
  • Enanta Pharmaceuticals' Accumulated Expenses stood at $2.4 million in 2021, then grew by 7.02% to $2.6 million in 2022, then skyrocketed by 1308.1% to $36.5 million in 2023, then crashed by 71.04% to $10.6 million in 2024, then decreased by 28.37% to $7.6 million in 2025.
  • The last three reported values for Accumulated Expenses were $7.6 million (Q4 2025), $6.5 million (Q3 2025), and $27.8 million (Q2 2025) per Business Quant data.